Antibiotics in the clinical pipeline in 2011

被引：204

作者：

Butler, Mark S. ^{[1
]}

Cooper, Matthew A. ^{[1
]}

机构：

[1] Univ Queensland, Div Chem & Struct Biol, Inst Mol Biosci, Brisbane, Qld 4072, Australia

来源：

JOURNAL OF ANTIBIOTICS | 2011年 / 64卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

clinical trials; drug development; drug discovery; natural product; resistance; IN-VITRO ACTIVITIES; PEPTIDE DEFORMYLASE INHIBITOR; CARRIER PROTEIN REDUCTASE; TRANSFER-RNA SYNTHETASE; DE-NOVO DESIGN; STAPHYLOCOCCUS-AUREUS; FABI INHIBITOR; LIPID-II; BAD BUGS; MYCOBACTERIUM-TUBERCULOSIS;

D O I：

10.1038/ja.2011.44

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The emergence of multi-drug-resistant bacteria and the lack of new antibiotics in the antibiotic drug development pipeline, especially those with new modes of action, is a major health concern. This review lists the 20 new antibiotics launched since 2000 and records the 40 compounds currently in active clinical development. Compounds in the pipeline from new antibiotic classes are reviewed in detail with reference to their development status, mode of action, spectrum of activity and lead discovery. In addition, the NP or synthetic derivation is discussed, with activity against Gram-negative bacteria highlighted. The Journal of Antibiotics (2011) 64, 413-425; doi:10.1038/ja.2011.44; published online 18 May 2011

引用

页码：413 / 425

页数：13

共 201 条

[71] New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile [J].

Johnson, Alan P. .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (10) :1389-1399

[72] A guiding hand for antibiotics [J].

Jones, Dan .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (03) :161-162

[73] The antibacterial lead discovery challenge [J].

Jones, Dan .

NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :751-752

[74] Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains [J].

Jones, Ronald N. ;

Biedenbach, Douglas J. ;

Ambrose, Paul G. ;

Wikler, Matthew A. .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 62 (01) :110-112

[75] NEW BROAD SPECTRUM ANTIBACTERIAL SOAP .1. GENERAL PROPERTIES [J].

JUNGERMANN, E ;

TABER, D .

JOURNAL OF THE AMERICAN OIL CHEMISTS SOCIETY, 1971, 48 (07) :318-+

[76] In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis [J].

Karlowsky, James A. ;

Laing, Nancy M. ;

Baudry, Trish ;

Kaplan, Nachum ;

Vaughan, David ;

Hoban, Daryl J. ;

Zhanel, George G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) :1580-1581

[77] AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity [J].

Karlowsky, James A. ;

Kaplan, Nachum ;

Hafkin, Barry ;

Hoban, Daryl J. ;

Zhanel, George G. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3544-3548

[78] A new anti-MRSA antibiotic complex, WAP-8294A - I. Taxonomy, isolation and biological activities [J].

Kato, A ;

Nakaya, S ;

Kokubo, N ;

Aiba, Y ;

Ohashi, Y ;

Hirata, H ;

Fujii, K ;

Harada, K .

JOURNAL OF ANTIBIOTICS, 1998, 51 (10) :929-935

[79] WAP-8294A(2), a novel anti-MRSA antibiotic produced by Lysobacter sp. [J].

Kato, A ;

Nakaya, S ;

Ohashi, Y ;

Hirata, H .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (28) :6680-6681

[80] RAMOPLANIN (A-16686), A NEW GLYCOLIPODEPSIPEPTIDE ANTIBIOTIC .4. COMPLETE SEQUENCE DETERMINATION BY HOMONUCLEAR 2D NMR-SPECTROSCOPY [J].

KETTENRING, JK ;

CIABATTI, R ;

WINTERS, G ;

TAMBORINI, G ;

CAVALLERI, B .

JOURNAL OF ANTIBIOTICS, 1989, 42 (02) :268-275

← 3 4 5 6 7 8 9 10 11 12 →